Alembic Pharmaceuticals has informed the exchange that the Company's joint venture, Aleor Dermaceuticals has received US Food and Drug Administration (USFDA) Final Approval for Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram. In this regard, the company has enclosed a press release.
The above information is a part of company’s filings submitted to BSE.